Annexon ANNX EBITDA

EBITDA at other companies

Regeneron PharmaceuticalsREGN

$1.42B+16.7%

Shattuck Labs, Inc.STTK

-$15.3M-26.4%

Jade BiosciencesJBIO

-$43.44M-85.8%

Dianthus TherapeuticsDNTH

-$46.5M-40.3%

Cullinan Therapeutics, Inc.CGEM

-$57.18M+24.5%

Vor BiopharmaVOR

-$35.13M-8.2%

FAQ

What is Annexon's EBITDA?

Annexon (ANNX) reported EBITDA of -$45.51M in Q1 2026.

How has Annexon's EBITDA changed year-over-year?

Annexon's EBITDA increased by 20.0% year-over-year, from -$56.87M to -$45.51M.

What is the long-term trend for Annexon's EBITDA?

Over 4 years (2021 to 2025), Annexon's EBITDA has grown at a 13.6% compound annual growth rate (CAGR), from -$128.57M to -$214.24M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.